Your browser doesn't support javascript.
loading
Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer.
Geraghty, Leeann; Schultz, Thomas E; Hoffman, Sarah E; Porter, Kyle; Issa, Majd; Karivedu, Vidhya; Bonomi, Marcelo.
Afiliación
  • Geraghty L; Department of Pharmacy, Norton Cancer Institute, Louisville, KY 40241, USA.
  • Schultz TE; Department of Pharmacy, the James Cancer Hospital at The Ohio State University, Columbus, OH 43210, USA.
  • Hoffman SE; Department of Pharmacy, the James Cancer Hospital at The Ohio State University, Columbus, OH 43210, USA.
  • Porter K; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA.
  • Issa M; Department of Internal Medicine, Division of Medical Oncology, the James Cancer Hospital at The Ohio State University, Columbus, OH 43210, USA.
  • Karivedu V; Department of Internal Medicine, Division of Medical Oncology, the James Cancer Hospital at The Ohio State University, Columbus, OH 43210, USA.
  • Bonomi M; Department of Internal Medicine, Division of Medical Oncology, the James Cancer Hospital at The Ohio State University, Columbus, OH 43210, USA.
Mol Clin Oncol ; 15(5): 240, 2021 Nov.
Article en En | MEDLINE | ID: mdl-34650807
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Mol Clin Oncol Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Mol Clin Oncol Año: 2021 Tipo del documento: Article